Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Sanofi and Regeneron Pharmaceuticals have initiated a clinical programme of rheumatoid arthritis drug Kevzara (sarilumab) to treat hospitalised patients with severe Covid-19 coronavirus infection.
Kevzara is a fully-human monoclonal antibody, which inhibits the interleukin-6 (IL-6) pathway. The drug is being co-developed by Sanofi and Regeneron.
IL-6 is associated with the overactive inflammatory response in the lungs of severely or critically ill Covid-19 patients. According to the companies, the trial will be initially performed at medical centres in New York, US.